ArticlePeerJ2025
Simpler predictive models provide higher accuracy for ovarian cancer detection.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MUC16 promotes endometrial cancer progression and modulates sensitivity to lapatinib through the ESR1/PI3K/AKT axis.Translational oncology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer remains a danger to women's health, and accurate screening tests would likely increase survival. Two established protein biomarkers, CA125 and HE4, have been shown to work well in isolation, but achieve even higher accuracy when combined using logistic regression (LR). This LR-based combination of protein concentrations achieves high accuracy when distinguishing healthy samples from cancer samples (area under the curve (AUC) = 0.99). The dataset we use was obtained from a previous publication that described DELFI-Pro, an LR model combining features derived from cell-free DNA (cfDNA) with the two proteins' concentrations. We show that many of DELFI-Pro's cfDNA features are affected by confounding technical variation within training data, which impacts the previously reported results. A minority of the training data's cancer samples (42 of 94) have chromosomal copy number values that are markedly different from the other samples used to evaluate the DELFI-Pro screening model. After removing those 42 samples from the training data, we find that DELFI-Pro does not outperform CA125 or CA125+HE4 protein-only screening classifiers even in cross validation, including a two-protein model published alongside the DELFI-Pro model. We conclude that DELFI-Pro does not adequately justify the inclusion of its cfDNA features. Our results are in line with the principle that simpler machine learning models will tend to exhibit better generalizability on new data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.